Onera Health Inc. has raised $9.3M+ in Series A funding. Led by Jazz Pharmaceuticals, imec.xpand, as well as other investors including imec and BOM, this funding is a key step towards bringing the healthcare startup closer to realizing its mission – to revolutionize sleep diagnostics with the world’s first at-home medical grade sleep diagnostic patch system.
The need for better sleep testing is great. One in five people struggle to get through the day because a sleep disorder affects them at night. Whether it’s insomnia, sleep apnea, narcolepsy or a host of other disorders, people suffering with these conditions don’t often seek out a proper diagnosis. For many, the process of being tested at a sleep clinic is uncomfortable, inconvenient, intimidating and expensive, and even motivated patients often need to wait months for an appointment.
“We believe the solutions Onera Health are developing could transform diagnostic and treatment-monitoring processes in sleep medicine,” said Jed Black, M.D., Senior Vice President, Sleep and CNS Medicine at Jazz Pharmaceuticals and adjunct professor, Stanford University Medical Center, Stanford Center for Sleep Sciences and Medicine. “Onera’s hardware and software innovations, as well as its streamlined service model, have the potential to empower clinicians to provide patients with optimal sleep care.”
Headquartered in California’s Silicon Valley, with R&D offices in the Netherlands, Onera focuses on breakthrough sleep testing solutions that are quick, convenient and clinically accurate. Two simple patches will replace cumbersome sensors usually attached to the face, scalp, chest and limbs. Doctors will benefit from test results matching the accuracy of conventional in-lab sleep clinics while patients will rest easier being monitored at home or in a medical setting suggested by their doctor. Ultimately, patients and physicians alike will enjoy easier access to accurate sleep diagnostics at a fraction of the cost.
Source: Onera Health Inc.